Finance

Lists
Why is AQST down 3.08%?
Dive Deeper
AQST:NASDAQ
Aquestive Therapeutics Inc
$3.77
-3.08%
(-0.12) 1D
$3.84
+1.86% (+0.070)
After hours
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AQST...
Open
$3.92
High
$3.96
Low
$3.64
Mkt. cap
473.18M
Avg. vol.
2.13M
Volume
0.00
52-wk high
$6.85
52-wk low
$2.93
EPS
-$0.65
Beta
1.49
Shares outstanding
125.51M
No. of employees
147
Open
$3.92
High
$3.96
Low
$3.64
Mkt. cap
473.18M
Avg. vol.
2.13M
Volume
0.00
52-wk high
$6.85
52-wk low
$2.93
EPS
-$0.65
Beta
1.49
Shares outstanding
125.51M
No. of employees
147
News stories
From web sources and news partners
About Aquestive Therapeutics Inc
CEO-
Employees147
Founded2004
HeadquartersWarren, New Jersey, United States
SectorPharmaceutical industry
Websiteaquestive.com
Analyst ratings
Based on 3 analysts giving stock ratings to AQST in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for AQST in the last 3 months.
Highest
Current $3.77
$10.00 (+165.25%)
Average
$8.67 (+129.97%)
Lowest
$6.00 (+59.15%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$10.00
+165.3%
10/16/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$10.00
+165.3%
09/17/2026
Thomas Flaten
Lake Street
Buy
Maintained
$6.00
+59.2%
09/17/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$11.00
+191.8%
06/25/2026
Andreas Argyrides
Chardan Capital
Buy
Reiterated
$8.00
+112.2%
06/25/2026
Roanna Ruiz
Leerink Partners
Buy
Reiterated
$9.00
+138.7%
05/15/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$8.00
+112.2%
05/15/2026
James Molloy
Alliance Global Partners
Buy
Maintained
$9.00
+138.7%
05/14/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
12.81M
13.02M
14.45M
13.82M
Cost of goods sold
4.51M
5.84M
3.47M
4.02M
Cost of revenue
4.51M
5.84M
3.47M
4.02M
Research and development expenses
4.53M
3.20M
4.20M
3.96M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
15.25M
32.82M
10.98M
14.06M
Operating expense
19.78M
36.02M
15.18M
18.02M
Total operating expenses
24.29M
41.85M
18.65M
22.04M
Operating income
-11.48M
-28.84M
-4.20M
-8.22M
Other non operating income
-
-
-
-
EBT including unusual items
-15.45M
-31.86M
-8.06M
-22.86M
EBT excluding unusual items
-15.45M
-31.86M
-8.06M
-11.18M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-15.45M
-31.86M
-8.06M
-22.86M
Net profit margin
-120.61%
-244.79%
-55.77%
-165.45%
Earnings per share
-0.11
-0.14
-0.05
-0.07
Interest and investment income
306.00K
1.25M
83.00K
882.00K
Interest expense
-4.27M
-4.27M
-3.94M
-3.84M
Net interest expenses
-3.97M
-3.02M
-3.85M
-2.96M
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.34M
-28.68M
-4.09M
-8.09M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps